MARKET WIREYahoo Finance • 6h ago
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?Yahoo Finance report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
Why ZBH Stock dropped -3.03% Today — RQD Quant Desk Flash
$94.52 -3.03% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $94.23
Zimmer Biomet Holdings Inc. (ZBH) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (70% profit margin, 5% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $18.59B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZBH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Zimmer Biomet Holdings Inc. (NYSE: ZBH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $94.52 (-3.03% 1D, market cap $18.59B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ZBH ranks #76 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZBH compare to STE and SNN in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), ZBH carries a Roarable B- (71/100 RQD), trailing P/E of 26.4x, gross margin of 69.7%, and ROIC of 4.6%. By comparison, STE (STERIS plc (Ireland)) holds a B grade (72/100 RQD, P/E 28.9x, ROIC 10.1%, cap $22.63B) and SNN (Smith & Nephew SNATS Inc.) posts a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $12.73B). Among the 5-stock peer group, MSA leads on earnings multiple (24.8x) while MSA leads on capital efficiency (16.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZBH?
▼
Per ZBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001136869), Zimmer Biomet Holdings Inc. generated $8.23B in revenue (+7.2% YoY), $705.1M in net income, and $1.47B in free cash flow against $23.09B in total assets and $6.93B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $94.23 (-0.31%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 17.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B- · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZBH)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY ZBH SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (21% of score)
20D Institutional Volume Accumulation (±4.8% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (21% of score)
FRED Regime × Technicals: 63% of 52W Range • RSI-14 at 57 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Cash Engine Quality12/20 pts (-8 pt drag)
Capital intensity & 13.3% operating margin leave 8 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$92.08+4.3% Next Q
63
Q2 (-2Q)Grade B-$96.00+0.1% Next Q
66
Q3 (-1Q)Grade B-$96.06-1.6% Next Q
68
CurrentGrade B-$94.52+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ZBH Bull Thesis Could Fail
Even with a 71/100 (B-) score, ZBH faces multiple-compression risk if 26.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 67.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($94.71) or 200D SMA ($91.73) invalidates the momentum regime and cuts Target Base ($100.05) toward Bear Floor ($77.51).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZBH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZBH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZBH Stock dropped -3.03% Today — RQD Quant Desk Flash
Zimmer Biomet Holdings Inc. (ZBH) dropped -3.03% to $94.52, trading at 63% of its 52-week range ($79.12 – $103.7). High-quality cash engine (70% profit margin, 5% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 63% of its 52-week range ($79.12 – $103.7) with RSI-14 at 57 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.8% around $94.52 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 69.7% gross margin and $1.5B annual free cash flow.
Live ZBH Headlines & Catalysts
MARKET WIREYahoo Finance Australia • 9h ago
Zimmer Biomet Holdings, Inc. (ZBH) stock price, news, quote and historyYahoo Finance Australia report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 12h ago
Zimmer Biomet Holdings Stock Price Forecast. Should You Buy ZBH?StockInvest.us report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 15h ago
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?TradingView report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
RISK WATCHGuruFocus • 18h ago
Zimmer Biomet Holdings Inc (ZBH) Shares Fall 3.0% -- What GF ScoGuruFocus report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.debelegger.nl • 21h ago
Zimmer Biomet Holdings (ZBH) Stock Price, Chart & Analysiswww.debelegger.nl report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Zimmer Biomet (ZBH) Stock Looks Below Fair Value After A 30% FallSimply Wall St report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12h ago
Is This Number The Biggest Risk To Intuitive Surgical Stock?For questions about this article or underlying research, email help@trefis.com.
CATALYSTYahoo • 2d ago
Zimmer Biomet (ZBH) Stock May Be A Bargain Despite Robot Surgery PushZimmer Biomet Holdings has been building out its orthopedic surgery technology, yet the share price is still shaped by a long, uneven return profile that raises a simple question about value. With the stock at US$94.52 a
RISK WATCHYahoo • 3d ago
Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations”Key TakeawaysStryker shares fell 5% after third-quarter sales and adjusted EPS missed estimates and it cut its 2026 guidance. Stryker blamed a slowing market, but Johnson & Johnson grew hips and knees faster in the same
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ZBH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZBH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.33%📐 HORIZONTAL RANGE
2026-11-02O $96.39H $97.47L $94.52C $94.52VOL 2.04M
RES: $98.65SUP: $86.78SMA50: $94.71SMA200: $91.73
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZBH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
20.0%/yr Implied 5Y Growth
vs. +7.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZBH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZBH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZBH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZBH)
Health Care Rank #76 of 1016
⚔️ STE vs ZBH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZBH vs. STE, SNN, ALGN, MSA)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Zimmer Biomet Holdings Inc. (ZBH) ranks #76 by composite RQD confidence (71/100, grade B-) and #73 by equity capitalization ($18.59B). Within this direct 5-issuer industry benchmark cohort, MSA leads on earnings valuation at 24.8x trailing P/E, while MSA leads on capital efficiency and profitability with 16.6% ROIC and 46.5% gross margin. STE currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with ZBH at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZBH
ACTIVE
Zimmer Biomet Holdings Inc. | B- | 71/100 | 26.4x | 69.7% | 4.6% | -3.03% | $18.59B | Benchmark Subject |
| STE STERIS plc (Ireland) | B | 72/100 | 28.9x | 44.2% | 10.1% | -2.16% | $22.63B | /ste-vs-zbh → |
| SNN Smith & Nephew SNATS Inc. | D+ | 58/100 | 32.8x | — | 9.9% | -2.33% | $12.73B | /snn-vs-zbh → |
| ALGN Align Technology Inc. | C+ | 66/100 | 26.6x | 67.2% | 11.1% | -2.48% | $10.92B | /algn-vs-zbh → |
| MSA MSA Safety Incorporated | B | 72/100 | 24.8x | 46.5% | 16.6% | -0.33% | $6.91B | /msa-vs-zbh → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001136869In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zimmer Biomet Holdings Inc. (ZBH) reported GAAP revenue of $8.23B (+7.2% vs. FY2024 revenue of $7.68B , and +11.3% cumulative change since FY2023) , GAAP net income of $705.1M, operating cash flow of $1.70B, and free cash flow of $1.47B (+13.7% YoY). On the balance sheet, ZBH closed FY2025 with $23.09B in total assets against $6.93B in total debt (Altman Z-Score: 2.42, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $8.23B | $705.1M | $1.70B | $1.47B | $23.09B | $6.93B |
| FY2024 (FY) | 2024-12-31 | $7.68B | $903.8M | $1.50B | $1.30B | $21.37B | $5.34B |
| FY2023 (FY) | 2023-12-31 | $7.39B | $1.02B | $1.58B | $1.25B | $10.23B | $2.39B |
3. ZBH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Zimmer Biomet Holdings Inc. (NYSE: ZBH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $94.52 (-3.03% 1D, market cap $18.59B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ZBH ranks #76 in composite RQD confidence.
How does ZBH compare to STE and SNN in the Health Care sector?
Within the Health Care sector (Industrial Specialties), ZBH carries a Roarable B- (71/100 RQD), trailing P/E of 26.4x, gross margin of 69.7%, and ROIC of 4.6%. By comparison, STE (STERIS plc (Ireland)) holds a B grade (72/100 RQD, P/E 28.9x, ROIC 10.1%, cap $22.63B) and SNN (Smith & Nephew SNATS Inc.) posts a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $12.73B). Among the 5-stock peer group, MSA leads on earnings multiple (24.8x) while MSA leads on capital efficiency (16.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZBH?
Per ZBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001136869), Zimmer Biomet Holdings Inc. generated $8.23B in revenue (+7.2% YoY), $705.1M in net income, and $1.47B in free cash flow against $23.09B in total assets and $6.93B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZBH trading relative to its 50-day, 200-day, and 52-week technical levels?
ZBH last traded at $94.52 (-3.03% on volume of 3,605,961 shares), positioning the stock -0.20% below its 50-day simple moving average ($94.71) and +3.04% above its 200-day simple moving average ($91.73). Across its 52-week range of $79.12 to $103.70, ZBH sits at the 62.7% percentile with a 14-day RSI of 57.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($89.98 to $99.06).
ZBH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZBH stock moving today?
Why ZBH Stock dropped -3.03% Today — RQD Quant Desk Flash. High-quality cash engine (70% profit margin, 5% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 71/100 (B-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ZBH — Zimmer Biomet Holdings Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:13:55Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ZBH scores 71 out of 100, a B- grade with the verdict label "Roarable Buy — Sound Institutional Accumulation." The five pillars are:
- Fundamental Cash Engine: 12 / 20. Per the RQD rating, this pillar reflects ROIC of 4.6% and an FCF yield of 7.92%. For a prospective investor, the cash generation is meaningful relative to the price, but the low ROIC indicates that the return on invested capital is modest, which limits how much of the cash engine is translating into value creation.
- Whale 13F Flow: 15 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score suggests institutional interest is constructive, though the source data does not itemize specific 13F holdings (see Analyst View section).
- Insider Conviction: 15 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates a moderately supportive insider signal; the underlying transactions are not itemized in the source data.
- Macro Regime Fit: 15 / 20. Per the RQD rating, this pillar reflects a beta of 1.02 and sector sensitivity. A beta near 1.0 implies the stock has historically moved roughly in line with the broad market, so it offers neither a defensive profile nor a high-volatility profile.
- Forensic Balance Sheet: 14 / 20. Per the RQD rating, this pillar reflects an Altman Z of 2.42, Piotroski F of 8/9, and Debt/Equity of 0.55. These are relatively healthy readings and are the strongest supporting factor in the rating.
Investor implications: The rating's upside drivers are the balance sheet quality, institutional support, and reasonable cash yield. The valuation tradeoff is that the stock trades at a P/E (TTM) of 26.4 and EV/EBITDA of 19.3 against a modest ROIC of 4.6%, so the market price already embeds significant expectations relative to current returns on capital. This is an analytical framing, not personalized financial advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $8231.5M | $1098.1M | $705.1M | N/A | $1472.6M | $591.9M | $6932.0M |
| FY 2024 | $7678.6M | $1285.7M | $903.8M | N/A | $1295.6M | $525.5M | $5341.6M |
| FY 2023 | $7394.2M | $1277.7M | $1024.0M | N/A | $1248.9M | N/A | $2392.7M |
Per the SEC financials, revenue grew from $7394.2M (FY 2023) to $8231.5M (FY 2025), while net income declined from $1024.0M to $705.1M over the same span. Reported debt rose from $2392.7M to $6932.0M across the three periods. Per the RQD rating and market data, ROIC is 4.6%, net margin is 8.6%, the Altman Z-Score is 2.42, the Piotroski F-Score is 8/9, and Debt/Equity is 0.55. The Z-Score and F-Score readings are relatively supportive, while the declining net income and rising debt are the trends a careful reader should weigh alongside them.
Open Questions
- What specific products and end markets generate ZBH's revenue, and how is the business segmented?
- Why did net income decline from FY 2023 to FY 2025 while revenue increased, and what drove the rise in debt from $2392.7M to $6932.0M?
- What is the reason behind the 3.0% share decline flagged in the GuruFocus headline, and is it linked to a fundamental event?
- How do the reported EPS figures (listed as N/A in the financials) reconcile with the EPS (TTM) of 3.7 in market data?
- What institutional and insider transactions underpin the Whale 13F Flow and Insider Conviction pillar scores?
ZBH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Zimmer Biomet Holdings Inc. (ZBH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 6h ago
Should Value Investors Buy Zimmer Biomet (ZBH) Stock? Yahoo Finance report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Australia • 9h ago
Zimmer Biomet Holdings, Inc. (ZBH) stock price, news, quote and history Yahoo Finance Australia report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 12h ago
Zimmer Biomet Holdings Stock Price Forecast. Should You Buy ZBH? StockInvest.us report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 15h ago
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards? TradingView report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH GuruFocus • 18h ago
Zimmer Biomet Holdings Inc (ZBH) Shares Fall 3.0% -- What GF Sco GuruFocus report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.debelegger.nl • 21h ago
Zimmer Biomet Holdings (ZBH) Stock Price, Chart & Analysis www.debelegger.nl report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Zimmer Biomet (ZBH) Stock Looks Below Fair Value After A 30% Fall Simply Wall St report covering Zimmer Biomet Holdings Inc. (ZBH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 12h ago
Is This Number The Biggest Risk To Intuitive Surgical Stock? For questions about this article or underlying research, email help@trefis.com.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ZBH Bull vs. Bear Conversation Board — What's Your Call at $94.52?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZBH 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $115.01 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ZBH (B- • RQD 71/100) a Buy at $97.47?
Welcome to the ZBH (Zimmer Biomet Holdings Inc.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $74.08 (-24.0%)
Spot @ $97.47 Pump the brakes on ZBH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ZBH, but look at what you are paying: 26.4x trailing P/E with 69.7% gross margins. Unless Zimmer Biomet Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $123.79 (+27.0%)
Spot @ $97.47 ZBH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ZBH, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $97.47 (52-wk range $79.12 - $103.70), any beat on forward guidance forces shorts and underweight funds to chase.